HEATR1 deficiency enhanced gastric cancer cell PANoptosis to boost anti-tumor immunity
Ya Huang, Qingcheng Xu, Meijuan Zhu, Yawei Shen, Xianwen Zhang · 2026
Read HEATR1 deficiency enhanced gastric cancer cell PANoptosis to boost anti-tumor immunity by Ya Huang, Qingcheng Xu, Meijuan Zhu, Yawei Shen, Xianwen Zhang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13625226.txt.
Description
Immune checkpoint drugs help some stomach cancer patients, but too few killer T cells reach the tumor in many cases. The five authors ask whether blocking a protein called HEATR1 can change that. In stomach tumor tissue, higher HEATR1 went with fewer CD8 T cells, more advanced stage, and spread to lymph nodes. Lowering HEATR1 slowed tumors in mice with intact immune systems but not in mice lacking T cells, showing the effect runs through immunity.
The mechanism runs through STAT1, a signal protein that HEATR1 normally marks for breakdown. Without HEATR1, STAT1 lasts longer and primes cancer cells for an inflammatory death called PANoptosis when exposed to interferon gamma. That death releases danger signals that mature dendritic cells and train CD8 T cells, which then feed the cycle. Organoids from patients confirmed the pattern, and HEATR1 lowering worked well with anti-PD1 therapy.
Catalog record
| CREATOR | Ya Huang, Qingcheng Xu, Meijuan Zhu, Yawei Shen, Xianwen Zhang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 78 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |